Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.74 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4374230 | 0.85 | FOLH1 (1.00) | FOLH1MCL1 | |
| SCHEMBL4379752 | 0.85 | FOLH1 (1.00) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4373083 | 0.84 | FOLH1 (0.74) | FOLH1FFAR1FFAR4MCL1 | |
| SCHEMBL4370868 | 0.83 | FOLH1 (1.00) | FOLH1FFAR1FFAR4PTGER1PTGER4 | |
| SCHEMBL7041129 | 0.83 | FOLH1 (0.72) | FOLH1FFAR1FFAR4 | |
| SCHEMBL13954175 | 0.79 | FOLH1 (0.69) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4380794 | 0.79 | FOLH1 (0.70) | FOLH1 | |
| SCHEMBL2058308 | 0.79 | FOLH1 (1.00) | FOLH1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL4370856 | 0.78 | FOLH1 (0.78) | FOLH1MCL1 | |
| SCHEMBL4377997 | 0.78 | FOLH1 (0.81) | FOLH1PTGER1PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | claimed |
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | EISAI INC. | 2003-05-29 | — | — | US | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025666-A2 | Thiolalkyl benzoic acid derivatives | MGI GP, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1406867-B1 | THIOLALKYL BENZOIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-6740777-B2 | MERCAPTOALKYL BENZOIC ACID DERIVATIVE ARE USEFUL FOR INHIBITING NAALADASE (ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100607-A1 | Mercaptoalkyl benzoic acid derivative are useful for inhibiting NAALADase (acetylated alpha-linked acidic dipeptidase/N-/) enzyme activity | NAALAD2, DNPEP, ALDH7A1 | FOLH1 14/4885FFAR1 3263/4885FFAR4 3471/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885FFAR1 738/4885FFAR4 1354/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | FOLH1 254/4885FFAR1 3630/4885FFAR4 3136/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | FOLH1 124/4885FFAR1 3621/4885FFAR4 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.